

## AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions and listings of claims in the application:

### LISTING OF CLAIMS:

#### Appendix

1. (Currently amended) ~~Derivatives of~~ An oxazolidinone derivative represented by ~~corresponding~~ Formula 1, ~~and or~~ a pharmaceutically acceptable salts thereof[.]:

<Formula: 1>



(In the Formula 1, wherein,

X represents carbon or nitrogen[.];

R<sub>1</sub> and R<sub>1</sub>' , which are the same or different, respectively represent hydrogen or fluorine[.];

R<sub>2</sub> represents —NR<sub>5</sub> R<sub>6</sub>, —OR<sub>7</sub>, triazol, fluorine, alkylphosphate, monophosphate or a metal salt of phosphate;

R<sub>5</sub> and R<sub>6</sub>, which are the same or different, respectively represent hydrogen, ~~C-sub. 1-4a~~  
C<sub>1-4</sub> alkyl or acetyl; and

R<sub>7</sub> is hydrogen, ~~C-Sub 1-3a~~ C<sub>1-3</sub> alkyl or acylated amino acid, ~~wherein, When the R<sub>7</sub> is~~  
~~acylated amino acid,~~ the amino acid refers to alanine, glycine, proline, isoleucine, leucine,  
phenylalanine, β-alanine or valine[.];

Het, ~~which~~ is a heterocyclic ring or a hetero aromatic ring, selected from the group  
consisting of ~~refers to~~ pyrrole, furan, piperazine, piperidine, imidazole, 1,2,4-triazol, 1,2,3-triazol,  
tetrazole, pyrazole, pyrrolidine, oxazole, isoxazole, oxadiazole, pyridin, pyrimidine, thiazole  
and ~~or~~ pyrazine[.];

R<sub>3</sub> and R<sub>4</sub>, which are the same or different, respectively refer to hydrogen, ~~C-sub. 1-4a~~  
C<sub>1-4</sub> alkyl group that is unsubstituted, ~~or substituted or unsubstituted~~ with cyano, -(CH<sub>2</sub>)<sub>m</sub>-OR<sub>7</sub> (m  
represents 0, 1, 2, 3, 4) or ketone.

2. (original): The compound of claim 1, wherein X represents nitrogen.
3. (currently amended): The compound of claim 1, wherein R<sub>1</sub> and R<sub>1</sub>' are  
different from each other and each represents hydrogen or fluorine, ~~and R<sub>1</sub>' represents~~  
~~remaining atom thereof.~~
4. (original): The compound of claim 1, wherein R<sub>2</sub> represents -OR<sub>7</sub> and R<sub>7</sub> is  
hydrogen.

5. (original): The compound of claim 1, wherein  $R_2$  represents  $-OR_7$  and  $R_7$  is acylated amino acid.

6. (original): The compound of claim 5, wherein the amino acid is one selected from the group consisting of alanine, glycine, proline, isoleucine, leucine, phenylalanine,  $\beta$ -alanine and valine.

7. (original): The compound of claim 1, wherein  $R_2$  is one selected from the group consisting of an alkylphosphate, monophosphate and a metal salt of phosphate.

8. (original): The compound of claim 1, wherein Het is tetrazole or oxadiazole.

9. (currently amended): The compound of claim 8, wherein the tetrazole and oxadiazole ~~is represent as monosubstituted on hydrogen~~ with methyl.

10. (currently amended) The compound of claim 1, wherein  $R_3$  and  $R_4$ , different from each other, each represents hydrogen or ~~C-sub-1-4a~~  $C_{1-4}$  alkyl group that is unsubstituted or substituted ~~or unsubstituted with cyano, and  $R_4$  represents remaining thereof.~~

11. (currently amended): The compound of claim 1, wherein the pharmaceutically acceptable salt is formed with an acid ~~one~~ selected from the group consisting of hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, citric acid, acetic acid, lactic acid, maleic acid, fumaric acid, gluconic acid, methane sulfonic acid, glyeonic acid, succinic acid, 4-toluenesulfonic acid, trifluoroacetic acid, galuturonic acid, embonic acid, glutamic acid and aspartic acid.

12. (currently amended) The compound of claim 11, wherein the acid is ~~pharmaceutically acceptable salt is one selected from the group consisting of~~ hydrochloric acid ~~and or~~ trifluoroacetic acid.

13. (currently amended): The compound of claim 1, ~~wherein the derivative which~~ is ~~one~~ selected from the group consisting of

1) (S)-3-(4-(2-(2-oxo-4-glycyloxymethylpyrrolidin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid,

2) (S)-3-(4-(2-(4-glycyloxyethyl-1,2,3-triazol-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid,

3) (S)-3-(4-(2-(5-glycyloxyethylisoxazol-3-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid,

4) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-([1,2,4]triazol-1-yl)methyl oxazolidin-2-on,

- 5) (S)-3-(4-(2-(2-oxo-3-glycyloxypyrolidine-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid,
- 6) (S)-3-(4-(2-(5-glycyloxymethyl-[1,2,4-oxadiazole-3-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid,
- 7) (S)-3-(4-(2-(5-glycyloxymethyl-4,5-dihydroisoxazole-3-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid,
- 8) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-([1,2,3]triazol-2-yl)methyl oxazolidin-2-on,
- 9) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-([1,2,3]triazol-1-yl)methyl oxazolidin-2-on,
- 10) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-on,
- 11) (S)-3-(4-(4-(4,5-dimethyloxazol-2-yl)phenyl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide,
- 12) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid,
- 13) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-1([1,2,3]triazol-1-yl)methyl oxazolidin-2-on,
- 14) (R)-3-(4-(2-([1,2,4]triazol-1-yl)pyridin-5-yl)-3-fluorophenyl)-5-([1,2,3]triazol-1-yl)methyl oxazolidin-2-on,

- 15) (S)-3-(4-(2-(4,5-dimethyloxazol-2-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide,
- 16) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-on,
- 17) (R)-3-(4-(2-[1,2,4]triazol-1-ylpyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-on,
- 18) (R)-3-(4-(2-(2-inethyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-fluoromethyl oxazolidin-2-on,
- 19) (S)-3-(4-(2-(imidazole-1-yl)pyridin-5-yl)-3-fluorophenyl)-5-aminomethyl oxazolidin-2-on hydrochloride,
- 20) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-on trifluoroacetic acid,
- 21) (R)-3-(4-(4-(4,5-dimethyloxazol-2-yl)phenyl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-on,
- 22) (R)-3-(4-(2-([1,2,3]triazol-1-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid,
- 23) (R)-3-(4-(4-(4,5-dimethyloxazol-2-yl)phenyl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid,
- 24) (R)-3-(4-(2-([1,2,3]triazol-1-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl is oxazolidin-2-on,

- 25) (S)-3-(4-(2-([1,2,3]triazol-2-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide,
- 26) (S)-3-(4-(4-(4(S)-hydroxymethyl-4,5-dihydroxazole-2-yl)phenyl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide,
- 27) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazole-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid,
- 28) (S)-3-(4-(4-(4-hydroxymethylthiazol-2-yl)phenyl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide,
- 29) (R)-3-(4-(2-([1,2,3]triazol-2-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-on,
- 30) (S)-3-(4-(4-(4-glycyloxymethylthiazol-2-yl)phenyl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide trifluoroacetic acid,
- 31) (S)-3-(4-(4-(4-cyanomethylthiazol-2-yl)phenyl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl acetamide,
- 32) (R)-3-(4-(4-(4-cyanomethylthiazol-2-yl)phenyl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-on,
- 33) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-methoxymethyl oxazolidin-2-on,
- 34) (R)-3-(4-(4-(4-cyanomethylthiazol-2-yl)phenyl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid,

35) (R)-3-(4-(2-([1,2,3]triazol-2-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on trifluoroacetic acid,

36) (R)-3-(4-(4-(4-hydroxymethylthiazol-2-yl)phenyl)-3-fluorophenyl)-5-([1,2,3]triazol-1-yl)methyl oxazolidin-2-on,

37) (R)-3-(4-(4-(4-glycyloxymethylthiazol-2-yl)phenyl)-3-fluorophenyl)-5-([1,2,3]triazol-1-yl)methyl oxazolidin-2-on trifluoroacetic acid,

38) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3,5-difluorophenyl)-5-hydroxymethyl oxazolidin-2-on,

39) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3,5-difluorophenyl)-5-hydroxymethyl oxazolidin-2-on,

40) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(N,N-dimethylaminomethyl)oxazolidin-2-on,

41) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(N-methylaminomethyl)oxazolidin-2-on,

42) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-on trifluoroacetic acid,

43) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-on hydrochloride,

44) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-on hydrochloride,



- 45) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on hydrochloride,
- 46) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-prolinyloxy)methyl oxazolidin-2-on trifluoroacetic acid,
- 47) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-prolinyloxy)methyl oxazolidin-2-on hydrochloride,
- 48) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-on hydrochloride,
- 49) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridine-5-yl)-3-fluorophenyl)-5-(β-alanyloxy)methyl oxazolidin-2-on trifluoroacetic acid,
- 50) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(β-alanyloxy)methyl oxazolidin-2-on hydrochloride,
- 51) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-on trifluoroacetic acid,
- 52) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-on hydrochloride,
- 53) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-on trifluoroacetic acid,
- 54) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-on hydrochloride,

- 55) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-prolinyl)oxazolidin-2-one trifluoroacetic acid,
- 56) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-prolinyl)oxazolidin-2-one hydrochloride,
- 57) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyl)oxazolidin-2-one trifluoroacetic acid,
- 58) (R)-3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyl)oxazolidin-2-one hydrochloride,
- 59) (R)-[3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl disodiumphosphate,
- 60) (R)-[3-(4-(2-(2-methyl-[1,3,4]oxadiazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl disodiumphosphate,
- 61) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one,
- 62) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one trifluoroacetic acid,
- 63) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one hydrochloride,
- 64) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyl)oxazolidin-2-one trifluoroacetic acid,


- 65) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-on hydrochloride,
- 66) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-on trifluoroacetic acid,
- 67) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-on hydrochloride,
- 68) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-on trifluoroacetic acid,
- 69) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-on hydrochloride,
- 70) (R)-[3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl disodiumphosphate,
- 71) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-([1,2,3]triazol-1-yl)methyl oxazolidin-2-on,
- 72) mono-[(R)-[3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl phosphate, and
- 73) mono-[(R)-[3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl] phosphate.

14. (canceled). ~~A method of preparing derivatives of oxazolidinone comprising;~~  
~~substituting a halogen atom for a hydrogen atom on phenyl of a derivative (II) of hydroxy-~~  
~~methyloxazolidinone thereby to form a derivative (III)(Step 1);~~

~~substituting stannyl for a halogen atom (Y) of the derivative (III) to form a derivative~~  
~~(IV)(Step 2);~~

~~reacting the derivative (IV) with pyridine or phenyl derivative that is substituted to~~  
~~bromine or iodine, to form a derivative (V) of oxazolidinone having pyridine ring or~~  
~~phenyl ring (Step. 3);~~

~~and reacting the derivative (V) with amino acid having a protecting group and then with~~  
~~acid thereby to eliminate the protecting group and to form salts of the compounds corresponding~~  
~~to Formula 1, or subjecting the derivative (V) to react with phosphate and then with metallic salt~~  
~~thereby to form salts of the compounds corresponding to Formula 1 (Step 4).~~




In the Scheme 1, Z represents C. sub. 1-4  $C_{1-4}$  alkyl group, X,  $R_1$ ,  $R_1'$ ,  $R_2$ ,  $R_3$  and  $R_4$  are as defined in Formula 1 and Y represents halogen.

15. (canceled).


16. (currently amended): A pharmaceutical composition comprising the compound derivatives of oxazolidinone corresponding Formula 1, and pharmaceutically acceptable salt of claim 1 thereof for use in an antibiotic.

17.(new) A method for preparing an oxazolidinone derivative of Formula (I):




or a pharmaceutically acceptable salt thereof, which comprises


reacting a compound of Formula (III):




with a tin compound to provide a compound of Formula (IV):



reacting the compound of Formula (IV) with a compound of Formula (VI):



to give a compound of Formula (V):



reacting the compound of Formula (V) with an amino acid or a phosphate to give the compound of Formula (I), and optionally reacting the compound of Formula (I) with an acid to form a pharmaceutically acceptable salt,

wherein, in the Formulas (I), (III), (IV), (V) and (VI),

X represents carbon or nitrogen;

$R_1$  and  $R_1'$ , which are the same or different, respectively represent hydrogen or fluorine;

$R_2$  represents  $-NR_5R_6$ ,  $-OR_7$ , triazol, fluorine, alkylphosphate, or monophosphate;

$R_5$  and  $R_6$ , which are the same or different, respectively represent hydrogen, a  $C_{1-4}$  alkyl or acetyl; and

$R_7$  is hydrogen, a  $C_{1-3}$  alkyl or acylated amino acid, wherein, the amino acid refers to alanine, glycine, proline, isoleucine, leucine, phenylalanine,  $\beta$ -alanine or valine;


Het is a heterocyclic ring or a hetero aromatic ring, selected from the group consisting of pyrrole, furan, piperazine, piperidine, imidazole, 1,2,4-triazol, 1,2,3-triazol, tetrazole, pyrazole, pyrrolidine, oxazole, isoxazole, oxadiazole, pyridin, pyrimidine, thiazole and pyrazine;

$R_3$  and  $R_4$ , which are the same or different, respectively refer to hydrogen, a  $C_{1-4}$  alkyl group that is unsubstituted, or substituted with cyano,  $-(CH_2)_m-OR_7$  ( $m$  represents 0, 1, 2, 3, or 4) or ketone;

Z represents a C<sub>1-4</sub> alkyl group; and

Y represents a halogen.

18. (new): The method of claim 17, wherein the compound of Formula (III) is obtained by halogenating a compound of Formula (II):



wherein R<sub>1</sub> and R<sub>1</sub>' each have the same meanings as defined in claim 17.

19 (new): The method of claim 17, wherein R<sub>1</sub> is fluorine, R<sub>1</sub>' is either hydrogen or fluorine, and Y represents a halogen.


20. (new): The method of claim 17, wherein Y is iodine.

21. (new): The method of claim 17, wherein the tin compound is represented by Formula (Z<sub>3</sub>Sn)<sub>2</sub> or Z<sub>3</sub>SnH, wherein Z has the same meaning as defined in claim 17.

22. (new): The method of claim 17, which further comprises reacting the compound of Formula (V) in which R<sub>2</sub> is a phosphate, with a metallic salt to give a compound of Formula (V) in which R<sub>2</sub> is a metal salt of phosphate.




23. (New) The compound of claim 1, having the structure



wherein R<sub>1</sub> is hydrogen, and R<sub>2</sub> is hydroxyl, an alkylphosphate, or monophosphate.

24. (New) The compound of claim 23, which has *R* stereochemistry.


25. (New) The compound of claim 1, having the structure



wherein R<sub>1</sub> is fluorine, and R<sub>2</sub> is hydroxyl, an alkylphosphate, or monophosphate.

26. (New) The compound of claim 25, which has *R* stereochemistry.


27. (New) The compound of claim 1, having the structure



wherein R<sub>1</sub> is hydrogen, and R<sub>2</sub> is hydroxyl, an alkylphosphate, or monophosphate.

28. (New) The compound of claim 27, which has *R* stereochemistry.


29. (New) The compound of claim 1, having the structure



wherein R<sub>1</sub> is fluorine, and R<sub>2</sub> is hydroxyl, an alkylphosphate, or monophosphate.

30. (New) The compound of claim 29, which has *R* stereochemistry.

31. (New) A compound having the structure



wherein,

$R_1$  is fluorine, and  $R_1'$  is either hydrogen or fluorine, and

Y represents a halogen.


32. (New) The compound of claim 31, which has *R* stereochemistry.

33. (New) The compound of claim 31, wherein Y is selected from the group consisting of Cl, Br, and I.

34. (New) The compound of claim 33, wherein Y is I.

35. (New) The compound of claim 31, wherein  $R_1$  is fluorine,  $R_1'$  is either hydrogen or fluorine, and Y is I.

36. (New) A method of preparing an oxazolidinone derivative or a pharmaceutically acceptable salt thereof of claim 1, which comprises using a compound having the structure




wherein  $R_1$  is fluorine,  $R_1'$  is either hydrogen or fluorine, and

Y represents halo.


37. (New) The method of claim 36, wherein Y is selected from the group consisting of Cl, Br, and I.

38. (New) The method of claim 37, wherein Y is I.

39. (New) A method of preparing an oxazolidinone derivative or a pharmaceutically acceptable salt thereof of claim 1, comprising the step of  
subjecting a compound of Formula (II):



to a halogenation to form a compound of Formula (III):



wherein,

R<sub>1</sub> is fluorine, R<sub>1</sub>' is either hydrogen or fluorine, and

Y represents a halogen.


40. (New) The method of claim 39, wherein compound (II) and compound (III) each have *R* stereochemistry.

41. (New) The method of claim 39, wherein Y is selected from the group consisting of Cl, Br, and I.

42. (New) The method of claim 41, wherein Y is I.

43. (New) The method of claim 39, wherein R<sub>1</sub> is fluorine, R<sub>1</sub>' is either hydrogen or fluorine, and Y is I.

44. (New) A method of preparing an oxazolidinone derivative or a pharmaceutically acceptable salt thereof of claim 1, comprising the step of treating a compound having the structure:



wherein R<sub>1</sub> and R<sub>1</sub>' each have the same meanings as defined in claim 1, with a tin compound.

45. (New) The method of claim 44, wherein the compound has *R* stereochemistry.

46. (New) The method of claim 44, wherein the tin compound has the formula  $(Z_3Sn)_2$  or  $Z_3SnH$ , and Z represents a  $C_{1-4}$  alkyl group.

47. (New) A method of treating a bacterial infection in a subject, comprising administering to the subject the composition of claim 16.

48. (New) The method of claim 47, wherein the bacterial infection results from a Gram-positive bacterium.

49. (New) The method of claim 48, wherein the Gram-positive bacterium is selected from the group consisting of *Staphylococcus*, *Enterococcus*, *Streptococcus*, *Bacteroides*, *Clostridium*, and *Mycobacterium*.

50. (New) The method of claim 49, wherein the bacterium is selected from the group consisting of *Staphylococcus*, *Enterococcus*, and *Streptococcus*.